Factual, peer-reviewed answers to the questions people search for most — from chronic pain and CBD to drug interactions, adolescent risk, and the legal landscape.
What the clinical evidence actually shows
Chronic pain is the most studied indication for medical cannabis. Multiple systematic reviews and meta-analyses support modest but meaningful pain reduction, particularly for neuropathic pain. Evidence is weaker for musculoskeletal and inflammatory pain.
Separating hype from peer-reviewed evidence
CBD has demonstrated anxiolytic effects in preclinical models and several human studies, but large-scale RCTs for anxiety disorders are still limited. Most human evidence comes from acute dosing studies and small open-label trials.
How cannabis interacts with your body's own signaling network
The endocannabinoid system (ECS) is a lipid-based retrograde signaling system present in all vertebrates. It regulates pain, mood, appetite, memory, immune function, and sleep. Understanding the ECS is foundational to understanding how cannabis works.
Short-term aid or long-term disruption?
Cannabis is widely used as a sleep aid, but the evidence is more nuanced than popular belief suggests. THC may reduce sleep onset time but suppresses REM sleep. CBD shows promise for sleep in anxiety-related insomnia. Long-term use may worsen sleep quality.
Mechanisms, effects, and clinical applications compared
THC and CBD are the two most abundant and studied cannabinoids. They have distinct receptor pharmacology, psychoactive profiles, and clinical applications. Understanding their differences is essential for informed cannabis use.
Evidence for trauma symptom relief
PTSD is one of the most common qualifying conditions for medical cannabis programs. The ECS plays a role in fear extinction and emotional memory — providing a biological rationale. Clinical evidence is growing but still limited by small sample sizes.
The strongest clinical evidence in cannabinoid medicine
Epilepsy — specifically Dravet syndrome and Lennox-Gastaut syndrome — represents the area of strongest clinical evidence for cannabinoid medicine. Epidiolex (purified CBD) received FDA approval in 2018 based on three Phase 3 RCTs.
Symptom management vs. anti-tumor claims
Cannabis has well-supported evidence for cancer-related symptom management (nausea, pain, appetite). Anti-tumor claims circulating online are based on preclinical (cell/animal) data and have not been demonstrated in human clinical trials.
Risks, benefits, and the psychosis debate
The relationship between cannabis and mental health is bidirectional and complex. While CBD shows therapeutic potential for anxiety and psychosis, high-potency THC use — especially in adolescents — is associated with increased risk of psychotic disorders.
Do cannabis terpenes actually change your experience?
Terpenes are aromatic compounds in cannabis that contribute to flavor and scent. The "entourage effect" hypothesis proposes they modulate cannabinoid activity. Evidence is primarily preclinical — human clinical data is limited.
One of the best-evidenced medical applications
Chemotherapy-induced nausea and vomiting (CINV) is one of three indications with "substantial evidence" per the 2017 National Academies report. Two FDA-approved synthetic cannabinoids (dronabinol and nabilone) are indicated for CINV. Whole-plant cannabis also shows benefit in observational data.
Emerging evidence for brain injury, neurodegeneration, and TBI
Preclinical evidence suggests cannabinoids — particularly CBD and endocannabinoids — have neuroprotective properties via antioxidant, anti-inflammatory, and anti-excitotoxic mechanisms. Human clinical evidence remains very limited, but the field is active.
The munchies paradox: why cannabis users weigh less on average
THC reliably stimulates appetite via hypothalamic CB1 receptors — the basis for dronabinol's FDA approval for HIV/AIDS-related anorexia. Paradoxically, epidemiological studies consistently find lower obesity rates among cannabis users. THCV may have appetite-suppressing properties.
What smoking cannabis actually does to your lungs
Smoking cannabis produces many of the same combustion byproducts as tobacco. Regular cannabis smoking is associated with chronic bronchitis symptoms. However, the relationship between cannabis smoking and lung cancer is less clear than for tobacco, and moderate use does not appear to cause the same degree of lung function decline.
Heart rate, blood pressure, and cardiac risk
Cannabis acutely increases heart rate and can transiently raise blood pressure, posing risks for individuals with pre-existing cardiovascular disease. Case reports link cannabis use to myocardial infarction, arrhythmia, and stroke — particularly in young users. Long-term cardiovascular effects are less clear.
Emerging research on endocannabinoids and gut health
The endocannabinoid system (ECS) plays a significant role in regulating gut motility, permeability, and inflammation. Emerging research suggests bidirectional communication between the ECS and gut microbiome — the "gut-endocannabinoid axis." Most evidence is preclinical.
Effects on testosterone, fertility, and sexual function
Cannabis affects the hypothalamic-pituitary-gonadal (HPG) axis, with potential effects on testosterone, sperm quality, menstrual cycles, and fertility. Evidence is mixed and often contradictory — effects appear dose-dependent and may differ by sex.
What the evidence shows after a decade of legal markets
A decade of legal cannabis markets in Colorado, Washington, and other states provides real-world data on legalization's public health effects. Evidence is mixed: some harms have increased (cannabis use disorder, adolescent access concerns), while others have not materialized (gateway drug fears, major crime increases).
Why the same dose affects people so differently
Individual responses to cannabis vary enormously — from no effect to overwhelming intoxication at the same dose. Pharmacogenomics explains much of this variation: CYP2C9 polymorphisms affect THC metabolism, CNR1 variants affect CB1 receptor sensitivity, and FAAH variants affect endocannabinoid tone.
CYP450 enzyme inhibition and clinically significant interactions
Cannabis — particularly CBD — is a significant inhibitor of CYP450 liver enzymes (CYP2C9, CYP2C19, CYP3A4), which metabolize the majority of pharmaceutical drugs. This creates clinically important drug interactions that can increase or decrease medication levels, with potentially serious consequences.
Fetal development risks and current clinical guidance
Cannabis use during pregnancy and breastfeeding is not considered safe by any major medical organization. THC crosses the placenta and accumulates in fetal tissue; it is also detectable in breast milk. Prenatal exposure is associated with adverse neurodevelopmental outcomes in children.
Why youth use carries disproportionate risk
The human brain continues developing until approximately age 25, with the prefrontal cortex (executive function, impulse control) maturing last. Adolescent cannabis use — particularly regular use — is associated with cognitive impairment, increased addiction risk, and elevated mental health vulnerability that may persist into adulthood.
Legal definitions, chemical differences, and what they mean for consumers
Hemp, marijuana, and CBD are frequently confused. Hemp and marijuana are both Cannabis sativa but differ legally by THC content. CBD is a specific molecule found in both. Understanding these distinctions is essential for navigating legal status, product selection, and health claims.
Evidence-based dosing principles and the biphasic dose-response
Cannabis dosing is highly individualized due to pharmacogenomic variation, tolerance, route of administration, and the biphasic dose-response of THC. "Start low, go slow" is the universal clinical recommendation. There is no universally optimal dose — the minimum effective dose varies widely between individuals.
DSM-5 recognized symptoms, timeline, and management
Cannabis withdrawal is a clinically recognized syndrome (DSM-5) that occurs in a significant proportion of regular users who stop abruptly. While not medically dangerous, it is a major driver of relapse and can substantially impair quality of life during cessation.
What the research shows about crash risk and detection
Cannabis impairs driving-relevant cognitive and psychomotor functions. Epidemiological studies consistently show increased crash risk with cannabis use. However, the relationship between blood THC levels and impairment is weaker than for alcohol, complicating legal per se limits.
The strongest evidence base outside of epilepsy
Multiple sclerosis (MS) represents one of the best-evidenced indications for cannabis-based medicine. Nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is approved in over 30 countries for MS-related spasticity. The 2017 National Academies report found "substantial evidence" for cannabis in MS spasticity.